Advertisement

Topics

Reata Announces Clinical Trial Design for FALCON a Phase 3 Trial of Bardoxolone Methyl

12:17 EST 4 Jan 2019 | Investing News Network

Reata Pharmaceuticals (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) regarding the design of a Phase 3 clinical trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD). As quoted in the press release: … Continued

The post Reata Announces Clinical Trial Design for FALCON a Phase 3 Trial of Bardoxolone Methyl appeared first on Investing News Network.

Original Article: Reata Announces Clinical Trial Design for FALCON a Phase 3 Trial of Bardoxolone Methyl

NEXT ARTICLE

More From BioPortfolio on "Reata Announces Clinical Trial Design for FALCON a Phase 3 Trial of Bardoxolone Methyl"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...